News Briefing channel feed

Mer­sana CEO to step down af­ter eight years; Roy­al­ty Phar­ma pays $150M for Skytro­fa roy­al­ties

Last year

Macro­Gen­ics gets $15M from Gilead; Zenas, Bris­tol My­ers sign li­cens­ing deal in Asia-Pa­cif­ic

Last year

​​FDA to al­low 23andMe to re­port more BR­CA vari­ants; Janssen se­cures deal with AI-drug dis­cov­ery out­fit

Last year

Flag­ship re­fo­cus­es stealth RNA biotech; Mesoblast en­acts pay cuts for ex­ec­u­tives

Last year

CCM Bio­sciences breaks out of stealth with $25M; Two biotechs merge, to fo­cus on Parkin­son's

Last year

Gink­go teams up with Google Cloud; Two biotechs raise mon­ey through pri­vate place­ments

Last year

Take­da to com­mer­cial­ize Im­muno­Gen’s Ela­here in Japan; Val­ne­va shares safe­ty da­ta for its chikun­gun­ya vac­cine

Last year

Mer­ck kick-starts PhI­II cho­les­terol tri­als for its oral PC­SK9; Bax­ter re­calls 13,000+ vials of chemother­a­py

Last year

Ake­bia ex­pects to file vadadu­s­tat again to FDA by end of Q3; So­ci­etal CD­MO seeks to se­cure 8M+ in lat­est raise

Last year

Ipsen gives back Parkin­son’s drug af­ter fail­ing PhI­Ib study; Par­a­digm Ther­a­peu­tics gets glob­al rights to skin treat­ment

Last year

No­vavax says up­dat­ed Covid-19 jab works against two sub­vari­ants; Ul­ti­movacs re­vis­es PhII can­cer vac­cine read­out

Last year

FDA OKs In­grez­za for treat­ing chorea as­so­ci­at­ed with Hunt­ing­ton’s; Abi­vax inks agree­ment for up to $163M in debt fi­nanc­ing

Last year

Mer­ck­'s Welireg meets co-pri­ma­ry end­point in kid­ney can­cer PhI­II; Noveome rais­es half of planned $40M VC round

Last year

Val­ne­va tops up loan by $100M; Ipsen gets a vouch­er

Last year

Pre­ci­sion Bio­Sciences hands glob­al rights to CAR-T can­di­date; Sagimet clos­es un­der­writer’s op­tion to buy stock

Last year

Sino­vac's Covid vac­cine sales nose­dive; Gra­cell trims pipeline, starts lu­pus study

Last year

Ake­bia no­ti­fies SEC it will be late fil­ing Q2 earn­ings; Sur­rozen cuts two ear­ly pro­grams

Last year

HIV cell ther­a­py biotech Ad­dim­mune to go pub­lic via SPAC merg­er; WHO names new Covid-19 'vari­ant of in­ter­est'

Last year

Eli Lil­ly’s Moun­jaro peak sales could now top $68B – an­a­lyst; Elon Musk’s brain-chip com­pa­ny reels in $280M

Last year

Beam takes its time to the clin­ic; As­pen gets clear­ance to test Parkin­son's cell ther­a­py in hu­mans

Last year

BioN­Tech ex­pands ADC deal with Du­al­i­ty­Bio; Gra­cell and IO Biotech get pri­vate place­ments from a slew of in­vestors

Last year

George Church-en­dorsed start­up seeks 'al­ter­na­tives'; DOJ clos­es On­pat­tro mar­ket­ing in­ves­ti­ga­tion

Last year

In­ovio prunes head­count again; Au­los adds to Se­ries A

Last year

An­nex­on lays out more GA drug da­ta; Okyo Phar­ma pulls back pub­lic of­fer­ing

Last year
First page Previous page 14151617181920 Next page Last page
A service from the Financial Times